诊断阿尔茨海默病新药Amyvid

Amyvid,a new agent for the diagnosis of Alzheimer's disease

Amyvid是首个脑部淀粉样斑块显影剂,于2012年4月6日通过美国食品药品管理局(FDA)批准用于诊断阿尔茨海默病(Alzheimer's disease,AD)。文中综述了阿尔茨海默病的现状以及Amyvid的理化性质、作用机制、药动学、药效学、不良反应、临床评价等内容。

Amyvid is a radioactive diagnostic agent for Positron Emission Tomography （PET） imaging of the brain to estimate the density of β-amyloid neuritic plaque in adult patients with cognitive impairment who are being evaluated for Alzheimer＇s disease （AD） and other causes of cognitive decline. It was approved by U. S. Food and Drug Administration （FDA） on April 6, 2012. We reviewed the present situation of AD research, and the physical and chemical properties, mechanism of action, pharmacokinetics, pharmacodynamics, adverse reactions and clinical evaluation of Amyvid in this paper.